The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects

Ahmed Al-Qaissi, Saeed Alqarni, Zeeshan Javed, Stephen Atkin, Thozhukat Sathyapalan, Rebecca V. Vince, Leigh A. Madden

Research output: Contribution to journalArticle

Abstract

Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D, n = 105), women with polycystic ovary syndrome (PCOS, n = 145) and healthy volunteers (n = 69). All data were generated via the same flow cytometry protocol with the same antibody clones. Endothelial markers CD105 (Endoglin) and CD106 (Vascular cell adhesion molecule-1) were used to enumerate MP in venous blood. Results: The ratio of CD105MP:CD106MP was significantly different between groups (F = 63.43, p < 0.0001). Women with PCOS were found to have a median CD105MP:CD106MP ratio of 0.40 (IQR 0.24–0.57), suggesting approximately two CD106MP were found per CD105MP. The T2D group showed a median ratio of 2.32 (1.51–3.69) whereas in healthy volunteers the ratio was 2.21 (1.63–3.55). Serum intercellular adhesion molecule-1 was also shown to be significantly increased in PCOS when compared with control or T2D groups (F = 14.5, p < 0.001). Conclusion: These data suggest that women with PCOS have an altered endothelial MP release in favour of CD106. Thus a potential activated endothelial state exists in women with PCOS with a shift towards a predominantly CD106MP profile.

Original languageEnglish
JournalEndocrine
DOIs
Publication statusAccepted/In press - 1 Jan 2019

Fingerprint

Polycystic Ovary Syndrome
Type 2 Diabetes Mellitus
Healthy Volunteers
Vascular Cell Adhesion Molecule-1
Intercellular Adhesion Molecule-1
Flow Cytometry
Clone Cells
Antibodies
Serum

Keywords

  • Endothelial microparticles
  • Polycystic ovary syndrome
  • VCAM-1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. / Al-Qaissi, Ahmed; Alqarni, Saeed; Javed, Zeeshan; Atkin, Stephen; Sathyapalan, Thozhukat; Vince, Rebecca V.; Madden, Leigh A.

In: Endocrine, 01.01.2019.

Research output: Contribution to journalArticle

Al-Qaissi, Ahmed ; Alqarni, Saeed ; Javed, Zeeshan ; Atkin, Stephen ; Sathyapalan, Thozhukat ; Vince, Rebecca V. ; Madden, Leigh A. / The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. In: Endocrine. 2019.
@article{39346433648e4f179c3b384d791808c7,
title = "The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects",
abstract = "Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D, n = 105), women with polycystic ovary syndrome (PCOS, n = 145) and healthy volunteers (n = 69). All data were generated via the same flow cytometry protocol with the same antibody clones. Endothelial markers CD105 (Endoglin) and CD106 (Vascular cell adhesion molecule-1) were used to enumerate MP in venous blood. Results: The ratio of CD105MP:CD106MP was significantly different between groups (F = 63.43, p < 0.0001). Women with PCOS were found to have a median CD105MP:CD106MP ratio of 0.40 (IQR 0.24–0.57), suggesting approximately two CD106MP were found per CD105MP. The T2D group showed a median ratio of 2.32 (1.51–3.69) whereas in healthy volunteers the ratio was 2.21 (1.63–3.55). Serum intercellular adhesion molecule-1 was also shown to be significantly increased in PCOS when compared with control or T2D groups (F = 14.5, p < 0.001). Conclusion: These data suggest that women with PCOS have an altered endothelial MP release in favour of CD106. Thus a potential activated endothelial state exists in women with PCOS with a shift towards a predominantly CD106MP profile.",
keywords = "Endothelial microparticles, Polycystic ovary syndrome, VCAM-1",
author = "Ahmed Al-Qaissi and Saeed Alqarni and Zeeshan Javed and Stephen Atkin and Thozhukat Sathyapalan and Vince, {Rebecca V.} and Madden, {Leigh A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12020-019-02059-9",
language = "English",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",

}

TY - JOUR

T1 - The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects

AU - Al-Qaissi, Ahmed

AU - Alqarni, Saeed

AU - Javed, Zeeshan

AU - Atkin, Stephen

AU - Sathyapalan, Thozhukat

AU - Vince, Rebecca V.

AU - Madden, Leigh A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D, n = 105), women with polycystic ovary syndrome (PCOS, n = 145) and healthy volunteers (n = 69). All data were generated via the same flow cytometry protocol with the same antibody clones. Endothelial markers CD105 (Endoglin) and CD106 (Vascular cell adhesion molecule-1) were used to enumerate MP in venous blood. Results: The ratio of CD105MP:CD106MP was significantly different between groups (F = 63.43, p < 0.0001). Women with PCOS were found to have a median CD105MP:CD106MP ratio of 0.40 (IQR 0.24–0.57), suggesting approximately two CD106MP were found per CD105MP. The T2D group showed a median ratio of 2.32 (1.51–3.69) whereas in healthy volunteers the ratio was 2.21 (1.63–3.55). Serum intercellular adhesion molecule-1 was also shown to be significantly increased in PCOS when compared with control or T2D groups (F = 14.5, p < 0.001). Conclusion: These data suggest that women with PCOS have an altered endothelial MP release in favour of CD106. Thus a potential activated endothelial state exists in women with PCOS with a shift towards a predominantly CD106MP profile.

AB - Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D, n = 105), women with polycystic ovary syndrome (PCOS, n = 145) and healthy volunteers (n = 69). All data were generated via the same flow cytometry protocol with the same antibody clones. Endothelial markers CD105 (Endoglin) and CD106 (Vascular cell adhesion molecule-1) were used to enumerate MP in venous blood. Results: The ratio of CD105MP:CD106MP was significantly different between groups (F = 63.43, p < 0.0001). Women with PCOS were found to have a median CD105MP:CD106MP ratio of 0.40 (IQR 0.24–0.57), suggesting approximately two CD106MP were found per CD105MP. The T2D group showed a median ratio of 2.32 (1.51–3.69) whereas in healthy volunteers the ratio was 2.21 (1.63–3.55). Serum intercellular adhesion molecule-1 was also shown to be significantly increased in PCOS when compared with control or T2D groups (F = 14.5, p < 0.001). Conclusion: These data suggest that women with PCOS have an altered endothelial MP release in favour of CD106. Thus a potential activated endothelial state exists in women with PCOS with a shift towards a predominantly CD106MP profile.

KW - Endothelial microparticles

KW - Polycystic ovary syndrome

KW - VCAM-1

UR - http://www.scopus.com/inward/record.url?scp=85071840873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071840873&partnerID=8YFLogxK

U2 - 10.1007/s12020-019-02059-9

DO - 10.1007/s12020-019-02059-9

M3 - Article

JO - Endocrine

JF - Endocrine

SN - 1355-008X

ER -